Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.1K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.0K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.0K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

2.8K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
2.8K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

465
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
465
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.8K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Attitudes of specialist memory-clinic patients with early symptomatic Alzheimer's disease towards lecanemab: results from a multicenter survey in Europe.

Scientific reports·2026
Same author

Study protocol: double-blind, randomized, prospective, placebo controlled parallel group phase II study to investigate the effect of glycerol phenylbutyrate (GPB) on neurofilament light chain (NfL) levels in patients with corticobasal syndrome (CBS).

Neurological research and practice·2026
Same author

From clinical phenotypes to molecular stratification: early differential diagnosis of four-repeat tauopathies.

Frontiers in aging neuroscience·2026
Same author

Measuring the Prodrome Promise and Challenges of the Prodromal Synucleinopathy Rating Scale.

Neurology·2026
Same author

Planimetric and Linear MRI Markers for Progressive Supranuclear Palsy Classification: A Large Multicohort International Study.

Radiology·2026
Same author

Feasibility of short imaging protocols for [<sup>18</sup>F]fluordeprenyl-D2 PET in autoimmune encephalitis and multiple system atrophy.

European journal of nuclear medicine and molecular imaging·2026

Related Experiment Video

Updated: Feb 19, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.7K

Symptomatic therapy of multiple system atrophy.

Guido Rohrer1, Günter U Höglinger2, Johannes Levin3

  • 1Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany.

Autonomic Neuroscience : Basic & Clinical
|November 7, 2017
PubMed
Summary

Multiple system atrophy (MSA) is a progressive neurodegenerative disease. This review covers frequent clinical symptoms and their symptomatic treatment options for MSA patients.

Keywords:
Alpha-synucleinAutonomic failureCerebellumMotor symptomsMultiple system atrophyParkinson

More Related Videos

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

8.2K

Related Experiment Videos

Last Updated: Feb 19, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.7K
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

8.2K

Area of Science:

  • Neurology
  • Neurodegenerative Diseases
  • Autonomic Dysfunction

Background:

  • Multiple system atrophy (MSA) is a rare, progressive neurodegenerative disorder.
  • It is defined by autonomic failure and a movement disorder (parkinsonism or cerebellar dysfunction).
  • Other neurological and psychiatric symptoms can significantly impact quality of life.

Purpose of the Study:

  • To provide an overview of the common clinical manifestations of MSA.
  • To discuss current symptomatic treatment strategies for MSA patients.

Main Methods:

  • Literature review of clinical symptoms and treatment options for MSA.
  • Synthesis of information on managing autonomic and motor deficits.
  • Overview of neuropsychiatric symptom management.

Main Results:

  • MSA presents with diverse symptoms including autonomic dysfunction (e.g., orthostatic hypotension) and motor impairments (e.g., bradykinesia, ataxia).
  • Neuropsychiatric symptoms like depression and cognitive decline are also prevalent.
  • Symptomatic treatments aim to manage these specific deficits, as no causal therapy exists.

Conclusions:

  • Effective management of MSA relies on addressing its multifaceted symptomatology.
  • Symptomatic treatment is crucial for improving the quality of life for patients with MSA.
  • Further research into disease-modifying therapies is warranted.